How smaller pharma teams are rethinking safety surveillance - Qinecsa

How smaller pharma teams are rethinking safety surveillance

Qinecsa VP Product Management QVW, Jonathan Messer, has been featured in Drug Discovery World’s latest issue, where he discusses that the rise in global regulatory expectations could catch smaller marketing authorisation holders risk off-guard with their reliance on rudimentary signal detection practices.

Read article

Recent Articles

The Productivity Crisis That Persists Even Now: What Will It Take to Free Up PV Professionals to Assess Safety, Rather Than Coordinate Data?

Embracing quantitative signal detection methods as a smaller MAH

Real-Time Safety Signals Drive Continuous PV Insight

From Complaint Handling to Active Surveillance

Continuous Safety Surveillance for Medical Devices

Are patient outcomes getting lost in safety data complexity?

PreviousStatistical Significance: Could Small Pharma make more of Signal Detection

NextApplying AI to adverse event case processing